|
DE2557341A1
(de)
*
|
1975-12-19 |
1977-06-30 |
Hoechst Ag |
Basisch substituierte indolderivate und verfahren zu ihrer herstellung
|
|
AU531214B2
(en)
|
1979-06-28 |
1983-08-11 |
Ciba-Geigy Ag |
Stabilizers for chlorinated thermoplast
|
|
HU895334D0
(en)
|
1986-07-30 |
1990-01-28 |
Sandoz Ag |
Process for the preparation of nasal pharmaceutical compositions
|
|
TW226019B
(enExample)
|
1992-03-23 |
1994-07-01 |
Sankyo Co |
|
|
DE4325204C2
(de)
|
1993-07-27 |
2002-11-28 |
Matthias Lehr |
Acylpyrrolalkansäuren und ihre Derivate als Hemmstoffe der Phospholipase A¶2¶
|
|
EP0639573A1
(de)
|
1993-08-03 |
1995-02-22 |
Hoechst Aktiengesellschaft |
Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament
|
|
US5852046A
(en)
|
1993-08-03 |
1998-12-22 |
Hoechst Aktiengesellschaft |
Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them
|
|
JPH07133274A
(ja)
|
1993-11-09 |
1995-05-23 |
Sankyo Co Ltd |
ピロール誘導体
|
|
DE4338770A1
(de)
|
1993-11-12 |
1995-05-18 |
Matthias Dr Lehr |
Indol-2-alkansäuren und ihre Derivate als Hemmstoffe der Phospholipase A¶2¶
|
|
DE69529056T2
(de)
|
1994-01-19 |
2003-11-13 |
Sankyo Co., Ltd. |
Pyrrolopyridazin-derivate
|
|
AU701025B2
(en)
|
1995-02-01 |
1999-01-21 |
University College Cardiff Consultants Limited |
Heterocyclic compounds
|
|
JP2000509371A
(ja)
|
1996-04-03 |
2000-07-25 |
メルク エンド カンパニー インコーポレーテッド |
ファルネシル―タンパク質トランスフェラーゼ阻害剤
|
|
US5859035A
(en)
|
1996-04-03 |
1999-01-12 |
Merck & Co., Inc. |
Arylheteroaryl inhibitors of farnesyl-protein transferase
|
|
US20040122096A1
(en)
|
1996-06-03 |
2004-06-24 |
Hoechst Aktiengesellschaft |
Use of inhibitors of the cellular Na+/H+ exchanger (NHE) for preparing a medicament for normalizing serum lipids
|
|
DE19622222A1
(de)
|
1996-06-03 |
1997-12-04 |
Hoechst Ag |
Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikament zur Normalisierung der Serumlipide
|
|
ES2208935T3
(es)
|
1996-08-01 |
2004-06-16 |
Merckle Gmbh |
Acidos acil-pirrol-dicarboxilicos y acidos acil-indol-dicarboxilicos, asi como sus derivados como inhibidores de la fosfolipasa a2 citosolica.
|
|
US5998462A
(en)
|
1996-12-16 |
1999-12-07 |
Allelix Biopharmaceuticals Inc. |
5-alkyl indole compounds
|
|
US6828344B1
(en)
|
1998-02-25 |
2004-12-07 |
Genetics Institute, Llc |
Inhibitors of phospholipase enzymes
|
|
CA2322163A1
(en)
|
1998-02-25 |
1999-09-02 |
John Mckew |
Inhibitors of phospholipase a2
|
|
US6500853B1
(en)
|
1998-02-28 |
2002-12-31 |
Genetics Institute, Llc |
Inhibitors of phospholipase enzymes
|
|
US6589954B1
(en)
|
1998-05-22 |
2003-07-08 |
Scios, Inc. |
Compounds and methods to treat cardiac failure and other disorders
|
|
US6867209B1
(en)
|
1998-05-22 |
2005-03-15 |
Scios, Inc. |
Indole-type derivatives as inhibitors of p38 kinase
|
|
AUPP433398A0
(en)
|
1998-06-25 |
1998-07-16 |
Australian National University, The |
Compounds and processes
|
|
JP2000063354A
(ja)
|
1998-08-21 |
2000-02-29 |
Sumitomo Pharmaceut Co Ltd |
ピロール誘導体
|
|
JP2001151771A
(ja)
|
1999-09-10 |
2001-06-05 |
Kyowa Hakko Kogyo Co Ltd |
含窒素芳香族複素環誘導体
|
|
AU2252101A
(en)
|
1999-12-16 |
2001-06-25 |
Eli Lilly And Company |
New synthesis of SPLA2 inhibitors
|
|
RU2269523C2
(ru)
|
2000-04-28 |
2006-02-10 |
Акадиа Фармасьютикалз, Инк. |
Мускариновые агонисты
|
|
ES2172415B2
(es)
|
2000-07-28 |
2003-11-16 |
Univ Madrid Complutense |
Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina.
|
|
EP1377549A1
(en)
|
2001-03-12 |
2004-01-07 |
Millennium Pharmaceuticals, Inc. |
Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
|
|
TR200401028T2
(tr)
|
2001-11-09 |
2004-11-22 |
Scios Inc. |
Kistik fibrozun tedavisine yönelik metot
|
|
US7632955B2
(en)
|
2001-12-13 |
2009-12-15 |
National Health Research Institutes |
Indole compounds
|
|
US7528165B2
(en)
|
2001-12-13 |
2009-05-05 |
National Health Research Institutes |
Indole compounds
|
|
NZ538031A
(en)
|
2002-08-29 |
2007-10-26 |
Merck & Co Inc |
Indoles having anti-diabetic activity
|
|
EA010904B1
(ru)
*
|
2003-05-22 |
2008-12-30 |
НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. |
Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
|
|
CN100516041C
(zh)
|
2003-07-15 |
2009-07-22 |
大日本住友制药株式会社 |
新型杂芳基衍生物
|
|
US7576206B2
(en)
*
|
2003-08-14 |
2009-08-18 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
|
WO2005024416A1
(en)
|
2003-09-05 |
2005-03-17 |
Binghe Wang |
Water soluble boronic acid fluorescent reporter compounds and methods of use thereof
|
|
US20050203063A1
(en)
*
|
2003-09-12 |
2005-09-15 |
Raymond Deshaies |
Proteasome pathway inhibitors and related methods
|
|
TW200522944A
(en)
|
2003-12-23 |
2005-07-16 |
Lilly Co Eli |
CB1 modulator compounds
|
|
US7417063B2
(en)
|
2004-04-13 |
2008-08-26 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles useful as serine protease inhibitors
|
|
CA2570043A1
(en)
|
2004-06-08 |
2005-12-22 |
Chiron Corporation |
Env polypeptide complexes and methods of use
|
|
ES2246721B1
(es)
|
2004-08-10 |
2007-03-16 |
Laboratorios Del Dr. Esteve, S.A. |
Compuestos indolicos sustituidos, su preparacion y su uso como medicamentos.
|
|
US20090264384A1
(en)
|
2004-11-01 |
2009-10-22 |
Nuada, Inc. |
Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
|
|
JP2008521831A
(ja)
|
2004-11-30 |
2008-06-26 |
プレキシコン，インコーポレーテッド |
Ｐｐａｒ活性化合物
|
|
GB0500492D0
(en)
|
2005-01-11 |
2005-02-16 |
Cyclacel Ltd |
Compound
|
|
WO2006075638A1
(ja)
|
2005-01-14 |
2006-07-20 |
Dainippon Sumitomo Pharma Co., Ltd. |
新規ヘテロアリール誘導体
|
|
BRPI0607439A2
(pt)
|
2005-02-16 |
2010-04-06 |
Solvay Pharm Bv |
compostos, composição farmacêutica, método de preparação de composições farmacêuticas, e, uso de um composto
|
|
EP1893576A4
(en)
|
2005-05-27 |
2010-03-17 |
Univ Kingston |
TREATMENT OF PROTEIN DISORDERING
|
|
EP1924557A2
(en)
|
2005-09-16 |
2008-05-28 |
Serenex, Inc. |
Carbazole derivatives
|
|
EP1783114A1
(en)
|
2005-11-03 |
2007-05-09 |
Novartis AG |
N-(hetero)aryl indole derivatives as pesticides
|
|
CA2642668C
(en)
|
2006-02-15 |
2013-01-08 |
Allergan, Inc. |
Indole-3-carboxylic acid amide and ester compounds bearing phenyl groups having sphingosine-1-phosphate (s1p) receptor antagonist biological activity
|
|
WO2007112322A2
(en)
|
2006-03-28 |
2007-10-04 |
Allergan, Inc. |
Indole compounds having sphingosine-1-phosphate (s1p) receptor agonist and/or antagonist biological activity
|
|
ES2614931T3
(es)
|
2006-08-04 |
2017-06-02 |
Beth Israel Deaconess Medical Center |
Inhibidores de la piruvato cinasa y métodos de tratamiento de enfermedad
|
|
EP2049520A4
(en)
|
2006-08-07 |
2011-01-05 |
Ironwood Pharmaceuticals Inc |
indole compounds
|
|
WO2008024978A2
(en)
|
2006-08-24 |
2008-02-28 |
Serenex, Inc. |
Tetrahydroindolone and tetrahydroindazolone derivatives
|
|
EP1902733A1
(en)
|
2006-09-19 |
2008-03-26 |
Laboratorios Del Dr. Esteve, S.A. |
Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity
|
|
EP2113500A1
(en)
|
2006-10-31 |
2009-11-04 |
Takeda Pharmaceutical Company Limited |
MAPK/ERK kinase inhibitors
|
|
US8524917B2
(en)
|
2007-01-11 |
2013-09-03 |
Allergan, Inc. |
6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
|
|
JP2010518025A
(ja)
|
2007-02-05 |
2010-05-27 |
アミラ ファーマシューティカルス，インコーポレーテッド |
５−リポキシゲナーゼ活性化タンパク質（ｆｌａｐ）インヒビターとしての逆インドール
|
|
EP2134683A2
(en)
|
2007-02-12 |
2009-12-23 |
Intermune, Inc. |
Novel inhibitors hepatitis c virus replication
|
|
WO2008109702A1
(en)
|
2007-03-08 |
2008-09-12 |
Irm Llc |
Compounds and compositions as modulators of gpr119 activity
|
|
CN101016294A
(zh)
|
2007-03-13 |
2007-08-15 |
中国人民武装警察部队医学院 |
具有多种生物活性的取代吲哚－3－基草酰胺衍生物
|
|
KR20090125799A
(ko)
|
2007-03-29 |
2009-12-07 |
아스비오파마 가부시키가이샤 |
Ｃｐｌａ2 저해 활성을 가지는 인돌 유도체 및 그 용도 및 제조 방법
|
|
US8091582B2
(en)
|
2007-04-13 |
2012-01-10 |
Cla-Val Co. |
System and method for hydraulically managing fluid pressure downstream from a main valve between set points
|
|
WO2008133867A1
(en)
|
2007-04-26 |
2008-11-06 |
Merck & Co., Inc. |
2-substituted indole derivatives as calcium channel blockers
|
|
US8563594B2
(en)
|
2007-05-08 |
2013-10-22 |
Allergan, Inc. |
S1P3 receptor inhibitors for treating pain
|
|
US20100292129A1
(en)
*
|
2007-05-24 |
2010-11-18 |
Daniel Finley |
Methods and Compositions for Enhancing Proteasome Activity
|
|
TW200914437A
(en)
|
2007-06-20 |
2009-04-01 |
Ironwood Pharmaceuticals Inc |
FAAH inhibitors
|
|
EP2018861A1
(en)
|
2007-07-26 |
2009-01-28 |
Laboratorios del Dr. Esteve S.A. |
5HT6-Ligands such as sulfonamide derivatives in drug-induced weight-gain
|
|
ATE495737T1
(de)
|
2007-08-01 |
2011-02-15 |
Esteve Labor Dr |
Kombination von mindestens zwei 5-ht6-liganden
|
|
CN101917999A
(zh)
|
2007-11-07 |
2010-12-15 |
弗尔德里克斯制药股份有限公司 |
蛋白质运输的调节
|
|
CN101932325B
(zh)
|
2007-11-30 |
2014-05-28 |
新联基因公司 |
Ido抑制剂
|
|
EP2227467B1
(en)
|
2007-12-04 |
2014-12-31 |
F. Hoffmann-La Roche AG |
Isoxazolo-pyridine derivatives
|
|
GB0723815D0
(en)
|
2007-12-05 |
2008-01-16 |
Glaxo Group Ltd |
Compounds
|
|
US8642660B2
(en)
*
|
2007-12-21 |
2014-02-04 |
The University Of Rochester |
Method for altering the lifespan of eukaryotic organisms
|
|
JP2009179589A
(ja)
|
2008-01-30 |
2009-08-13 |
Pharma Ip |
抗ウイルス剤
|
|
US8658685B2
(en)
|
2008-01-31 |
2014-02-25 |
Activesite Pharmaceuticals, Inc. |
Methods for treatment of kallikrein-related disorders
|
|
KR101261514B1
(ko)
|
2008-02-25 |
2013-05-07 |
에프. 호프만-라 로슈 아게 |
피롤로피라진 키나아제 저해제
|
|
WO2009108551A2
(en)
|
2008-02-25 |
2009-09-03 |
H. Lundbeck A/S |
Heteroaryl amide analogues
|
|
JP2011514385A
(ja)
|
2008-03-17 |
2011-05-06 |
アラーガン、インコーポレイテッド |
炎症を処置するためのｓ１ｐ３受容体阻害剤
|
|
KR20100134680A
(ko)
|
2008-03-20 |
2010-12-23 |
포레스트 래보러토리즈 홀딩스 리미티드 |
스테아로일-ｃｏａ 불포화효소의 저해물질로서 신규한 피페리딘 유도체
|
|
AU2009228765B2
(en)
*
|
2008-03-24 |
2012-05-31 |
Novartis Ag |
Arylsulfonamide-based matrix metalloprotease inhibitors
|
|
US20090247766A1
(en)
|
2008-03-27 |
2009-10-01 |
University Of Southern California |
Substituted Nitrogen Heterocycles and Synthesis and Uses Thereof
|
|
US8367665B2
(en)
|
2008-04-16 |
2013-02-05 |
Karo Bio Ab |
Estrogen receptor ligands
|
|
JP5657524B2
(ja)
|
2008-04-24 |
2015-01-21 |
エフツージー リミテッド |
ピロール抗真菌剤
|
|
GB0808282D0
(en)
|
2008-05-07 |
2008-06-11 |
Medical Res Council |
Compounds for use in stabilizing p53 mutants
|
|
US20110086834A1
(en)
|
2008-06-26 |
2011-04-14 |
Amgen Inc. |
Alkynyl alcohols as kinase inhibitors
|
|
JP2011525928A
(ja)
|
2008-06-26 |
2011-09-29 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
Ａｋｔ活性の阻害剤
|
|
EP2141163A1
(de)
|
2008-07-02 |
2010-01-06 |
Bayer Schering Pharma AG |
Substituierte Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
|
|
WO2010015816A2
(en)
|
2008-08-06 |
2010-02-11 |
Summit Corporation Plc |
Treatment of lysosomal storage disorders and other proteostatic diseases
|
|
CA2733588A1
(en)
|
2008-08-12 |
2010-02-18 |
Merck Sharp & Dohme Corp. |
N-heterocyclic m1 receptor positive allosteric modulators
|
|
US8143269B2
(en)
|
2008-10-03 |
2012-03-27 |
Calcimedica, Inc. |
Inhibitors of store operated calcium release
|
|
TW201026695A
(en)
|
2008-12-12 |
2010-07-16 |
Astrazeneca Ab |
Piperidine compounds and uses thereof-596
|
|
US20120022057A1
(en)
|
2009-03-18 |
2012-01-26 |
Schering Corporation |
Bicyclic compounds as inhibitors of diacyglycerol acyltransferase
|
|
WO2010129553A1
(en)
|
2009-05-05 |
2010-11-11 |
Allergan, Inc. |
S1p3 receptor inhibitors for treating conditions of the eye
|
|
US8912220B2
(en)
|
2009-08-10 |
2014-12-16 |
Galenea Pharmaceuticals |
Compounds and methods of use thereof
|
|
WO2011038579A1
(en)
|
2009-09-30 |
2011-04-07 |
Zhejiang Beta Pharma Inc. |
Compounds and compositions as protein kinase inhibitors
|
|
AU2010308306A1
(en)
|
2009-10-19 |
2012-05-10 |
Synta Pharmaceuticals Corp. |
Combination cancer therapy with HSP90 inhibitory compounds
|
|
MX336731B
(es)
|
2010-01-28 |
2016-01-28 |
Harvard College |
Composiciones y metodos para potenciar la actividad de proteasoma.
|
|
US8785490B2
(en)
|
2010-04-09 |
2014-07-22 |
University Of Louisville Research Foundation, Inc. |
Compounds for treating disease, for administering, and for pharmaceutical compositions
|
|
EP2560640A1
(en)
|
2010-04-19 |
2013-02-27 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
|
|
WO2011133521A2
(en)
|
2010-04-19 |
2011-10-27 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
|
|
EP2575810A1
(en)
|
2010-05-24 |
2013-04-10 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor
|
|
EP2595993B1
(en)
*
|
2010-07-23 |
2018-04-18 |
President and Fellows of Harvard College |
Tricyclic proteasome activity enhancing compounds
|
|
AU2011302344B2
(en)
|
2010-09-13 |
2015-01-15 |
Synta Pharmaceuticals Corp. |
HSP90 inhibitors for treating non-small cell lung cancers in wild-type EGFR and/or KRAS patients
|
|
WO2012078757A2
(en)
|
2010-12-08 |
2012-06-14 |
Synta Pharmaceuticals Corp. |
Combination breast cancer therapy with hsp90 inhibitory compounds
|
|
EP2663305A1
(en)
|
2011-01-11 |
2013-11-20 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors
|
|
US9249087B2
(en)
|
2011-02-01 |
2016-02-02 |
The Board Of Trustees Of The University Of Illinois |
HDAC inhibitors and therapeutic methods using the same
|
|
EP2678013A1
(en)
|
2011-02-23 |
2014-01-01 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitory compounds with radiotherapy
|
|
EP2678014A2
(en)
|
2011-02-24 |
2014-01-01 |
Synta Pharmaceuticals Corp. |
Prostate cancer therapy with hsp90 inhibitory compounds
|
|
WO2012116247A1
(en)
|
2011-02-25 |
2012-08-30 |
Synta Pharmaceuticals Corp. |
Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers
|
|
RS58718B1
(sr)
|
2011-05-12 |
2019-06-28 |
Proteostasis Therapeutics Inc |
Regulatori proteostaze
|
|
US20140228418A1
(en)
|
2011-05-23 |
2014-08-14 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitory compounds with mek inhibitors
|
|
US20140315943A1
(en)
|
2011-05-24 |
2014-10-23 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitory compounds with mtor/p13k inhibitors
|
|
US20140194388A1
(en)
|
2011-05-26 |
2014-07-10 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitory compounds with chk inhibitors
|
|
US9260416B2
(en)
|
2011-05-27 |
2016-02-16 |
Amira Pharmaceuticals, Inc. |
Heterocyclic autotaxin inhibitors and uses thereof
|
|
JP2014520808A
(ja)
|
2011-07-07 |
2014-08-25 |
シンタ ファーマシューティカルズ コーポレーション |
Ｈｓｐ９０阻害化合物を用いた癌の治療
|
|
EP2548865B1
(en)
|
2011-07-22 |
2014-03-05 |
Université Joseph Fourier |
Novel bis-indolic derivatives, their uses in particular as antibacterials
|
|
JP2014534228A
(ja)
|
2011-11-02 |
2014-12-18 |
シンタ ファーマシューティカルズ コーポレーション |
白金含有剤とｈｓｐ９０阻害剤の組合せ療法
|
|
WO2013067162A1
(en)
|
2011-11-02 |
2013-05-10 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
|
|
EP2780010A1
(en)
|
2011-11-14 |
2014-09-24 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitors with braf inhibitors
|
|
US9849135B2
(en)
|
2013-01-25 |
2017-12-26 |
President And Fellows Of Harvard College |
USP14 inhibitors for treating or preventing viral infections
|